We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. An independent data monitoring committee has ruled that ...
The US Food and Drug Administration (FDA) on Monday issued a new draft guidance advising certain product sponsors to establish data monitoring committees (DMCs) to ensure that safety signals are ...
Participants in Cohort 1 have progressed to the open-label, Phase 2 portion of ELEVATE-45-201 -- -- Company on track to report ELEVATE-45-201 Cohort 1 data in mid-2026 -- BOSTON, June 02, 2026 (GLOBE ...
Data monitoring practices in clinical trials encompass the systematic oversight of accumulating participant data to safeguard safety, integrity and scientific validity. Core to these practices are ...
ChemoCentryx, the $3.7 billion biotech bought by Amgen in 2022, allegedly ignored repeated warnings from a data monitoring committee and withheld or manipulated trial results on the firm’s ...
Committee Recommends Expanding Sample Size After Interim Analysis Places Study in Protocol-Defined Promising Zone SAN DIEGO, June 1, 2026 /PRNewswire/ -- Ansun Biopharma, Inc., a clinical-stage ...
NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of ...
The European Medicines Agency (EMA) last week opened a consultation on a new question and answer document on data monitoring committees. The seven questions and answers deal with whether DMC ...
The National Academies of Sciences, Engineering, and Medicine will establish an ad hoc committee to lay out a framework to define and describe the data needs for a system to track and correlate viral ...
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, ...
SELLAS Life Sciences Group, Inc. has announced significant milestones in its clinical development of cancer therapies. An Independent Data Monitoring Committee will conduct an interim analysis of the ...
Participants in Cohort 1 have progressed to the open-label, Phase 2 portion of ELEVATE-45-201 -- -- Company on track to report ELEVATE-45-201 Cohort 1 data in mid-2026 -- BOSTON, June 02, 2026 (GLOBE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results